statement
SIM0725 was independently developed by the company.
A statement by 先聲藥業集團. Statements are as reported by the cited publishers — not verified by DecisionGateway.
其自主研發的
Discussion
Related claims
SIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.先聲藥業集團 · investigationSIM0725 is intended for the treatment of autoimmune diseases.先聲藥業集團 · statementThis company independently developed the related product.clsvip · statementSIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).先聲藥業集團 · statement双方已共同设立控股子公司和顺开源环保能源有限公司。武汉天源公告 · statementFull-category in-house R&D and production plus flexible manufacturing build the company's advantages.风口研报 · statement
More claims by 先聲藥業集團
SIM0725 is a long-acting antagonistic monoclonal antibody targeting the interleukin-2 receptor beta chain (CD122).statementSIM0725 is intended for the treatment of autoimmune diseases.statementSIM0725 has been approved by the National Medical Products Administration to conduct clinical trials in China.investigation
All claims by 先聲藥業集團